Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …

The natural mammalian polyamines putrescine, spermidine and spermine are essential for
both normal and neoplastic cell function and replication. Dysregulation of metabolism of …

Abstract Background KRAS p. G12C mutation occurs in approximately 1 to 2% of pancreatic
cancers. The safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient
survival. Toward understanding the underlying molecular alterations that drive PDAC …

Driver mutations promote initiation and progression of cancer. Pharmacological treatment
can inhibit the action of the mutant protein; however, drug resistance almost invariably …

RNA-binding proteins (RBPs) are critical effectors of gene expression, and as such their
malfunction underlies the origin of many diseases. RBPs can recognize hundreds of …

Pancreatic cancer is an increasingly common cause of cancer mortality with a tight
correspondence between disease mortality and incidence. Furthermore, it is usually …

Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second most common
cause of death within the next 10 years. The prognosis for this disease is poor despite …

Pancreatic adenocarcinoma presents as a spectrum of a highly aggressive disease in
patients. The basis of this disease heterogeneity has proved difficult to resolve due to poor …

Background About 25% of pancreatic cancers harbour actionable molecular alterations,
defined as molecular alterations for which there is clinical or strong preclinical evidence of a …